Antidepressants in long-term migraine prevention

Drugs

Volumn 69, Issue 1, 2009, Pages 1-19

  Koch, Horst J ^a   Jürgens, Tim P ^b,c  

^a HELIOS Klinikum Aue   (Germany)

^b Bezirksklinikum Regensburg ^*  (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CITALOPRAM; CLOMIPRAMINE; DOPAMINE; DOXEPIN; DULOXETINE; ERGOTAMINE DERIVATIVE; FEMOXETINE; FLUOXETINE; FLUVOXAMINE; METOPROLOL; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PROPRANOLOL; SEROTONIN; SERTRALINE; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BEDTIME DOSAGE; BLOOD DYSCRASIA; BLURRED VISION; C PEPTIDE BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DELIRIUM; DEPRESSION; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; HUMAN; ILEUS; INSOMNIA; INSULIN BLOOD LEVEL; LEPTIN BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MIGRAINE; MUSCLE HYPOTONIA; NAUSEA; PATHOPHYSIOLOGY; REVIEW; SEDATION; SIDE EFFECT; SWEATING; TACHYCARDIA; TENSION HEADACHE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG INTERACTIONS; HUMANS; MIGRAINE DISORDERS;

EID: 59749105581     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969010-00001     Document Type: Review

References (167)

1. Headache Classification Committee of the HIS. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 2004; 24 Suppl. 1: 24-36
2. Kelman L. The place of osmophobia and taste abnormalities in migraine classification: a tertiary care study of 1237 patients. Cephalalgia 2004; 24 (11): 940-6
3. Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia 2004; 24 (9): 728-34
4. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff's headache and other head pain. 7th ed. New York: Oxford University Press, 2001: 121-238
5. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: report of an EFNS task force. Eur J Neurol 2006; 13 (6): 560-72
6. Carod-Artal FJ, Ribeiro LD, Braga H, et al. Prevalence of patent foramen ovale in migraine patients with and without aura compared with stroke patients: a transcranial Doppler study. Cephalalgia 2006; 26 (8): 934-9
7. Gudmundsson LS, Thorgeirsson G, Sigfusson N, et al. Migraine patients have lower systolic but higher diastolic blood pressure compared with controls in a population-based study of 21 537 subjects: the Reykjavik Study. Cephalalgia 2006; 26 (4): 436-44
8. Ifergane G, Buskila D, Simiseshvely N, et al. Prevalence of fibromyalgia syndrome in migraine patients. Cephalalgia 2006; 26 (4): 451-6
9. Wolff HG. Headache and other head pain. 2nd ed. New York: Oxford University Press, 1963
10. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatr 1960; 23 (1): 23-32
11. Kashiwagi T, Wetzel RD, McClure JN. Headache and psychiatric disorders. Dis Nerv Syst 1972; 33 (10): 659-63
12. Couch JR, Ziegler DK, Hassanein RS. Evaluation of relationship between migraine headache and depression. Headache 1975; 15 (1):41-50
13. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36 (11): 695-9
14. Breslau N, Davis GC, Andreski P. Migraine disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res 1991; 37 (1): 11-23
15. Merikangas KR, Angst J, Isler H. Migraine and psychopathology: results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990; 47 (9): 849-53
16. Molgat CV, Patten SB. Comorbidity of major depression and migraine: a Canadian population-based study. Can J Psychiatry 2005; 50 (13): 832-7
17. Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia 2005; 25 (3): 165-78
18. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache 2006; 46 (9): 1327-33
19. Kalaydjian A, Merikangas K. Physical and mental comorbidity of headache in a nationally representative sample of US adults. Psychosom Med 2008; 70 (7): 773-80
20. Fiane I, Haugland ME, Stovner LJ, et al. Sick leave is related to frequencies of migraine and non-migrainous headache: the HUNT study. Cephalalgia 2006; 26 (8): 960-7
21. Breslau N, Lipton RB, Stewart WF, et al. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003; 60 (8): 1308-12
22. Tietjen GE, Herial NA, Hardgrove J, et al. Migraine comorbidity constellations. Headache 2007; 47 (6): 857-65
23. Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 2004; 19: 3-7
24. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl JMed 2002; 346 (4): 257-70
25. Goadsby PJ. Migraine pathophysiology. Headache 2005; 45: 14-24
26. Moskowitz MA. Genes proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. Funct Neurol 2007; 22 (3): 133-6
27. Durham PL. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 2008; 48 (8): 1269-75
28. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33 (1): 48-56
29. Rudolf K, Eberlein W, Engel W, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists: 1, potent and selective small molecule CGRP antagonists - 1-[N-2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)- oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl) piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 2005; 48 (19): 5921-31
30. Olesen J, Diener H, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN4096BSfor the acute treatment of migraine. NEJM 2004; 350 (11): 1104-10
31. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70 (16): 1304-12
32. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol- 5-yl)-1-oxo-1-(4-(piperidin-1-yl) piperidin-1-yl)propan-2-yl)piperidine-1- carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008; 51 (16): 4858-61
33. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703-9
34. Peroutka SJ. Drugs effective the therapy of migraine. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 488-502
35. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993; 13 (3): 151-65
36. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical physiological characterization. Trends Neurosci 1988; 11 (11): 496-500
37. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38 (8): 1083-152
38. Watling KJ. The RBI handbook of receptor classification and signal transduction. 3rd ed. Natick (MA): Sigma-Aldrich Research Biochemicals Inc., 1998
39. Sicuteri F. Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol 1959; 15 (4-5): 300-7
40. Sicuteri F, Anselmi B, Testi A. Biochemical investigations in headache-increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy Appl Immunol 1961; 19 (1): 55
41. Lance JW. Advances in biology and pharmacology of headache. Neurology 1993; 43 (6): 5
42. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27 (11): 1295-300
43. Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin: Springer, 2000
44. Pederson V. Psychotropics 2002/2003. Allerod: Lundbeck Institute, 2003
45. Bánk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34 (8): 476-8
46. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964; 1 (734): 1236-9
47. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36 (4): 684-90
48. Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 1987; 44 (5): 486-9
49. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine: pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50 (8): 825-30
50. Snow V, Weiss K, Wall EM, et al., American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137 (10): 840-9
51. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55 (6): 754-62
52. Krymchantowski AV, Silva MT, Barbosa JS, et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002; 42 (6): 510-4
53. Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 2004; 50 (4): 322-8
54. Evers S, Mylecharane EJ. Nonsteroidal anti-inflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, et al., editors. The headaches. 3rd edition. Philadelphia (PA): Lipincott Williams & Wilkins, 2006: 560
55. Hershey AD, Powers SW, Bentti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000; 40 (7): 539-49
56. Lewis DW, Diamond S, Scott D, et al. Prophylactic treatment of pediatric migraine. Headache 2004; 44 (3): 230-7
57. Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev 2003; (4): CD002761
58. Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005; 25 (11): 1048-53
59. Koch HJ. Steady state plasma levels during antidepressant therapy with amitriptyline and amitriptylinoxide. Israel J Psychiatry Rel Sci 1990; 27 (1): 48-53
60. Koch HJ. Alteration of the ECG and blood pressure during treatment with amitriptyline and amitriptylinoxide: a study with plasma levels. Irish J Psychiatry 1990; 11 (2): 12-6
61. Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin reuptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919
62. Gray AM, Pache DM, Sewell RDE. Do alpha(2)-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol 1999; 378 (2): 161-8
63. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7 (1): 51-4
64. Koch HJ. Relation between plasma levels and ECG after antidepressant treatment with amitriptyline and amitriptylinoxide [thesis]. Mainz: Medical Faculty, Johannes Gutenberg University, 1986
65. Shin JG, Park JY, Kim MJ, et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30 (10): 1102-7
66. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996; 60 (1): 48-53
67. Langohr HD, Gerber WD, Koletzki E, et al. Clomipramine and metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1985; 25 (2): 107-13
68. Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8 Suppl. 3: 49-52
69. Mørland TJ, Storli OV, Mogstad TE. Doxepin in the prophylactic treatment of mixed "vascular" and tension headache. Headache 1979; 19 (7): 382-3
70. Elser JM, Woody RC. Migraine headache in the infant and young-child. Headache 1990; 30 (6): 366-8
71. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000
72. Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39 (1): 28-32
73. Hays P. Paroxetine prevents migraines. J Clin Psychiatry 1997; 58 (1): 30-1
74. Black KJ, Sheline YI. Paroxetine as migraine prophylaxis. J Clin Psychiatry 1995; 56 (7):330-1
75. Zeeberg I, Orholm M, Nielsen JD, et al. Femoxetine in the prophylaxis of migraine: a randomised comparison with placebo. Acta Neurol Scand 1981; 64 (6): 452-9
76. Orholm M, Honoré PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand 1986; 74 (3): 235-9
77. Stankewitz A, May A. Cortical excitability and migraine. Cephalalgia 2007; 27 (12): 1454-6
78. Ozkul Y, Bozlar S. Effects of fluoxetine on habituation of pattern reversal visually evoked potentials in migraine prophylaxis. Headache 2002; 32 (7): 582-7
79. Oguzhanoglu A, Sahiner T, Kurt T, et al. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999; 19 (5): 531-2
80. Saper JR, Silberstein SD, Lake III AE, et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34 (9): 497-502
81. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32 (2): 101-4
82. d'Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39 (10): 716-9
83. Steiner TJ, Ahmed F, Findley LJ, et al. S-Fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18 (5): 283-6
84. Bickel A, Kornhuber J, Maihofner C, et al. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline: a case report. Pharmacopsychiatry 2005; 38 (6): 327-8
85. Munera PA, Goldstein A. Migraine and sertraline. J Am Acad Child Adolesc Psychiatry 2001; 40 (10): 1125-6
86. Delva NJ, Horgan SA, Hawken ER. Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors. Headache 2000; 40 (3): 248-51
87. Levy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol 2003; 18 (5): 301-3
88. Brannon GE, Rolland PD, Gary JM. Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics 2000; 41 (2): 153-4
89. Gorman JM. Mirtazapine: clinical overview. J Clin Psychiatry 1999; 60 Suppl. 17: 9-13; discussion 46-8
90. WebMD Inc. RxList: the internet drug index [online]. Available from URL: http://www.rxlist.com/script/main/hp.asp [Accessed 2008 Sep 2]
91. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand 1985; 320 Suppl.: 98-103
92. Martucci N, Manna V, Porto C, et al. Migraine and the noradrenergic control of vasomotricity: a study with alpha-2 stimulant and alpha-2 blocker drugs. Headache 1985; 25 (2): 95-100
93. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache 2001; 41 (5): 465-74
94. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997; 33 (4): 260-75
95. Choi S. Nefazodone (serzone) withdrawn becuase of hepatotoxicity. CMAJ 2003; 169 (11): 1187
96. FDA/Center for Drug Evaluation and Research. Drugs@FDA [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.Overview&DrugName=NEFAZODONE%20HYDROCHLORIDE [Accessed 2008 Sep 2]
97. Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008; 77 (1): 12-6
98. Taylor AP, Adelman JU, Freeman MC. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. Headache 2007; 47 (8): 1200-3
99. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. Epub 2008 Jul 15
100. Nascimento ED. Prophylaxis of migraine: open study with venlafaxine in 42 patients. Arq Neuropsiquiatr 1998; 56 (4): 744-6
101. Adelman LC, Adelman JU, Von Seggern R, et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000; 40 (7): 572-80
102. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (1): 44-8
103. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (2): 144-52
104. Diamond S, Pepper BJ, Diamond ML, et al. Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. Neurology 1998; 51 (1): 274-6
105. World Health Organization. Safety of venlafaxine. In: WHO Drug Information, vol 12, no 2. Geneva: WHO, 1998: 82
106. Ferrari A, Sternieri E, Ferraris E, et al. Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 2003; 48 (1): 1-9
107. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969; 21 (3): 263-8
108. Mann AM, Laing WA. Tranylcypromine cephalgia. Can Med Assoc J 1963; 89: 1115-8
109. Meienberg O, Amsler F. Moclobemide in the prophylactic treatment of migraine: a retrospective analysis of 44 cases. Eur Neurol 1996; 36 (2): 109-10
110. Meienberg O, Amsler F. Preventive treatment of migraine and chronic tension headache with moclobemide. Praxis (Bern 1994) 1997; 86 (27-28): 1107-12
111. Yoon MS, Savidou I, Diener HC, et al. Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005; 5 (3): 333-41
112. Fuseau E, Petricoul O, Moore KH, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41 (11): 801-11
113. Brewerton TD, Murphy DL, Mueller EA, et al. Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988; 43 (6): 605-9
114. Van Haarst AD, Van Gerven JM, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48 (2): 190-6
115. Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug-drug interactions. Headache 2002; 42 Suppl. 2: 63-73
116. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001; 51 (5): 437-41
117. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 1997; 17 Suppl. 18: 21-7
118. Merikangas KR, Stevens DE, Merikangas JR, et al. Tyramine conjugation deficit in migraine, tension-type headache, and depression. Biol Psychiatry 1995; 38 (11): 730-6
119. Goodman JF. Treatment of headache with bupropion [letter]. Headache 1997; 37 (4): 256
120. Pinsker W. Treatment of headache with bupropion [letter]. Headache 1998; 38 (1): 58
121. Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007; 27 (11): 1308-14
122. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61 (4): 476-87
123. Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35 (4): 500-4
124. Battistella PA, Ruffilli R, Cernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache 1993; 33 (1): 36-9
125. Pies R. Trazodone and intractable headaches. J Clin Psychiatry 1983; 44 (8): 317
126. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41 (3): 201-10
127. Costa E, Silva JA, Ruschel SI, et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997; 35 (1): 24-9
128. Ferrari A, Ottani A, Bertolini A, et al. Adverse reactions related to drugs for headache treatment: clinical impact. Eur J Clin Pharmacol 2005; 60 (12): 893-900
129. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30 (7): 1206-27
130. FDA/Center for Drug Evaluation and Research. Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake Inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome [online]. Available from URL: http://www.fda.gov/Cder/Drug/advisory/SSRI-SS200607.htm [Accessed 2008 Sep 5]
131. Evans RW. Triptans and serotonin syndrome. Cephalalgia 2008; 28 (5): 573-4; author reply 574-5
132. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148 (6): 705-13
133. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96 (9): 635-42
134. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007; 47 (2): 266-9
135. Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 1999; 19 (7): 668-75
136. Dahlof CG, Boes-Hansen S, Cederberg CG, et al. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998; 18 (5): 278-82
137. Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003; 43 (4): 423-7
138. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996; 16 (5): 323-7
139. Hewer W. Akut- und Notfallsituationen durch unerwünschte Arzneimittelwirkungen (UAW). In: Hewer R, Rössler W, editors. Das Notfallpsychiatrie Buch. München: Urban Schwarzenberg, 1998: 498-534
140. Yap YG, Camm AJ. Drug induced QT prolongation and torsade de pointes. Heart 2003; 89 (11): 1363-72
141. Arizona Center for Education and Research on Therapeutics. QT drug lists [online]. Available from URL: http://www.azcert.org/medical-pros/drug-lists/ drug-lists.cfm [Accessed 2008 Sep 2]
142. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23 (1): 58-77
143. Bareggi SR, Mundo E, Dell'Osso B, et al. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007; 3 (5): 741-53
144. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30 (7): 555-67
145. Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 2005; 87 (2-3): 243-52
146. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110 (10): 979-84
147. Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev 2003; 11 (2): 73-93
148. Gerstman BB, Jolson HM, Bauer M, et al. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol 1996; 49 (7): 809-15
149. Toda N, Tfelt-Hansen P. Calacim antagonists in migraine prophylaxis. In: Dlesen J, Goadsby PJ, Ramadan et al., editors. The headaches. 3rd edition. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 539-44
150. Keam SJ, Goa KL, Figgitt DP. Almotriptan: a review of its use in migraine. Drugs 2002; 62 (2): 387-414
151. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37-41
152. Krymchantowski A, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Med Gen Med 2004; 6 (3): 48
153. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134 (8): 663-94
154. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine. 2nd ed. Cephalalgia 2000; 20 (9): 765-86
155. American Academy of Neurology (AAN). Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology [online]. Available from URL: http://www.neurology.org/cgi/reprint/55/6/754.pdf [Accessed 2008 Dec 22]
156. Deutsche Gesellschaft für Neurologie (DGN). Therapie der Migräneattacke und Migracombining double acute accentneprophylaxe [online]. Available from URL: http://www.dgn.org/images/stories/dgn/leitlinien/migraene. pdf [Accessed 2008 Oct 4]
157. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment ofmigraine. BMJ (Clin Res Ed) 1985; 291 (6495): 569-73
158. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38 (9): 430-5
159. Rossi P, Di Lorenzo G, Malpezzi MG, et al. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia 2005; 25 (7): 493-506
160. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65 (9): 1239-82
161. Kalin P. The common butterbur (Petasites hybridus): portrait of a medicinal herb. Forsch Komplementarmed Klass Naturheilkd 2003; 10 Suppl. 1: 41-4
162. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27 (6): 391-401
163. Busch V, Gaul C. Exercise in migraine therapy: is there any evidence for efficacy? A critical review. Headache 2008; 48 (6): 890-9
164. Campbell JK, Penzien DB, Wall EM, et al. Headache Consortium. Evidenced-based guidelines for migraine headache: behavioral and physical treatments [online]. Available from URL: http://www.aan.com/professionals/ practice/pdfs/gl0089.pdf [Accessed 2008 Oct 4]
165. Strohle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. Epub 2008 Aug 23
166. Boerlin HL, Gitlin MJ, Zoellner LA, et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry 1998; 59 (7): 374-9
167. Sachs GS, Gardner-Schuster EE. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand 2007; 434 Suppl.: 27-34